Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
DLC1 contains 37 exons, spans approximately 59-kb, and is located in the 3p22-p21.3 chromosomal segment that is commonly deleted in various carcinomas. Additionally we are shipping and DLC1 Kits (1) and many more products for this protein.
Showing 10 out of 63 products:
Human Monoclonal DLC1 Primary Antibody for IF, WB - ABIN968714
Homma, Emori: A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. in The EMBO journal 1995
Show all 3 references for ABIN968714
Human Polyclonal DLC1 Primary Antibody for IHC (p), IHC - ABIN268701
Ko, Yeung, Wong, Chan, Poon, Ng, Yam: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. in Liver international : official journal of the International Association for the Study of the Liver 2009
Show all 2 references for ABIN268701
Human Polyclonal DLC1 Primary Antibody for IHC, IHC (p) - ABIN4305321
Muehlich, Hampl, Khalid, Singer, Frank, Breuhahn, Gudermann, Prywes: The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. in Oncogene 2012
it was demonstrated that the rs621554 polymorphism was correlated with DLC1 (show DYNLL1 Antibodies) expression at the mRNA level. These results suggested that the rs621554 polymorphism is associated with breast cancer susceptibility and prognosis, and may serve as a biomarker for breast cancer development and progression.
curcumin down-regulates the expression of Sp1 (show PSG1 Antibodies) to inhibit the expression of DNA methyltransferase 1 (show DNMT1 Antibodies), thus subsequently reducing hypermethylation of DLC1 (show DYNLL1 Antibodies) promoter to induce DLC1 (show DYNLL1 Antibodies) expression.
DLC-1 (show DYNLL1 Antibodies) acts as a tumor suppressor gene in HCC (show FAM126A Antibodies) by regulating the expression of RhoA (show RHOA Antibodies)/ROCK2 (show ROCK2 Antibodies)/ moesin (show MSN Antibodies).
Low DLC-1 (show DYNLL1 Antibodies) expression is associated with cancer.
Low expression of DLC1 (show DYNLL1 Antibodies) is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
No significant association of DLC1 (show DYNLL1 Antibodies) SNPs with the patients' prognosis was found.
A phosphorylation-mediated molecular switch comprising DLC), TNS3 (show TNS3 Antibodies), PTEN (show PTEN Antibodies) and PI3K (show PIK3CA Antibodies) controls the spatiotemporal activation of Rac1 and RhoA (show RHOA Antibodies), thereby initiating directional cell migration induced by growth factors.
Data suggest BCL2-like 1 (show BCL2L1 Antibodies) protein (BCL2L1 (show BCL2L1 Antibodies)) and deleted in liver cancer 1 protein (DLC1) as potential druggable targets for specific subsets of gastric cancer (GC) cases.
DLEC1 (show DLEC1 Antibodies) mediates tumor-suppressive activities through NF-kappaB (show NFKB1 Antibodies) signaling.
Low DLC1 (show DYNLL1 Antibodies) expression is associated with cancer.
studies demonstrate that TNS1 (show TNS1 Antibodies) binds to DLC1 and fine-tunes its RhoGAP (show ARHGAP1 Antibodies) activity toward RhoA (show RHOA Antibodies) and that the TNS1 (show TNS1 Antibodies)-DLC1-RhoA (show RHOA Antibodies) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (show RHOA Antibodies) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (show RHOA Antibodies) pathway that may be targeted therapeutically.
This gene contains 37 exons, spans approximately 59-kb, and is located in the 3p22-p21.3 chromosomal segment that is commonly deleted in various carcinomas. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins. Aberrant transcription of this gene may be involved in carcinogenesis of the lung, esophagus, and kidney.
deleted in liver cancer 1
, rho GTPase-activating protein 7-like
, Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, stAR-related lipid transfer protein 12
, deleted in liver cancer 1 protein homolog
, rho GTPase activating protein 7
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, deleted in lung and esophageal cancer 1 transcript varient 2
, deleted in lung and esophageal cancer protein 1